110 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
8 Mar 24
Other Events
5:27pm
directly to non-objecting beneficial owners:
No
Issuer will pay for objecting beneficial owner material distribution:
Yes
Issuer using notice-and-access … for registered investors:
No
Issuer using notice-and-access for non-registered investors:
Notice-and-access stratification criteria:
N/A
Thank you
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
webcast can be accessed on the Investors section of the Xenon website. Participants can access the live conference call by dialing (800) 715-9871
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
effective market access strategy and gain market acceptance for our future products, if any; and
manage our spending as costs and expenses increase due … could be adversely impacted in the future. Moreover, the prevalent use of mobile devices that access confidential information, widespread use of cloud
8-K
EX-1.1
312wsj4k
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
424B5
9hkh7w
29 Nov 23
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
8vdwqcxup46rnuj
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
ghm30n8 kco9zkq
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
yytpx80zxa6yi2
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
424B5
ew2ra6u2gqt
23 Jun 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
kpomh
23 Jun 22
Other Events
4:04pm
424B5
ez1 nps93
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-10.1
3m2n2 9pgwy
2 Jun 22
Departure of Directors or Certain Officers
4:03pm